Literature DB >> 9246143

Effects of high dose intravenous immunoglobulin in two severe corticosteroid insensitive asthmatic patients.

B Vrugt1, S Wilson, E van Velzen, A Bron, J K Shute, S T Holgate, R Djukanovic, R Aalbers.   

Abstract

Preliminary observations of the clinical efficacy of intravenous immunoglobulin in two patients with severe corticosteroid insensitive asthma are reported. In both patients treatment with intravenous immunoglobulin resulted in clinical improvement and enabled a significant reduction in the dose of prednisolone. In one of the patients fibreoptic bronchoscopy with endobronchial biopsies was performed and peripheral blood was analysed by flow cytometry before and after treatment. Immunohistological analysis of the biopsy samples after treatment showed a decrease in the number of all cell types, especially CD3+ T cells, CD4+ T cells, and activated CD25+ T lymphocytes, which was associated with a reduction in peripheral blood T cell activation. Intravenous immunoglobulin may be a valid option for the treatment of corticosteroid insensitive asthma. To elucidate the role and mode of action of intravenous immunoglobulin further studies in larger groups of patients are needed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9246143      PMCID: PMC1758603          DOI: 10.1136/thx.52.7.662

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  6 in total

1.  An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma.

Authors:  B D Mazer; E W Gelfand
Journal:  J Allergy Clin Immunol       Date:  1991-05       Impact factor: 10.793

2.  Neutrophil attractant protein-1-immunoglobulin G immune complexes and free anti-NAP-1 antibody in normal human serum.

Authors:  I Sylvester; T Yoshimura; M Sticherling; J M Schröder; M Ceska; P Peichl; E J Leonard
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

3.  Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro.

Authors:  C J Corrigan; P H Brown; N C Barnes; S J Szefler; J J Tsai; A J Frew; A B Kay
Journal:  Am Rev Respir Dis       Date:  1991-11

Review 4.  Immunomodulation with intravenous immunoglobulin.

Authors:  P D Hall
Journal:  Pharmacotherapy       Date:  1993 Nov-Dec       Impact factor: 4.705

5.  Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations.

Authors:  R Blasczyk; U Westhoff; H Grosse-Wilde
Journal:  Lancet       Date:  1993-03-27       Impact factor: 79.321

6.  Interleukin-8 is a potent eosinophil chemo-attractant.

Authors:  J Shute
Journal:  Clin Exp Allergy       Date:  1994-03       Impact factor: 5.018

  6 in total
  7 in total

Review 1.  Difficult asthma: beyond the guidelines.

Authors:  I Balfour-Lynn
Journal:  Arch Dis Child       Date:  1999-02       Impact factor: 3.791

Review 2.  Asthma that is unresponsive to usual care.

Authors:  Kenneth R Chapman; Andrew McIvor
Journal:  CMAJ       Date:  2009-10-13       Impact factor: 8.262

Review 3.  Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.

Authors:  L P Boulet; A Becker; D Bérubé; R Beveridge; P Ernst
Journal:  CMAJ       Date:  1999-11-30       Impact factor: 8.262

Review 4.  The protective role of immunoglobulins in fungal infections and inflammation.

Authors:  Sri Ramulu Elluru; Srini V Kaveri; Jagadeesh Bayry
Journal:  Semin Immunopathol       Date:  2014-11-18       Impact factor: 9.623

5.  Safety and ethics of bronchoscopy and endobronchial biopsy in difficult asthma.

Authors:  D Payne; S A McKenzie; S Stacey; D Misra; E Haxby; A Bush
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

6.  Intravenous immunoglobulin for cystic fibrosis lung disease: a case series of 16 children.

Authors:  I M Balfour-Lynn; U Mohan; A Bush; M Rosenthal
Journal:  Arch Dis Child       Date:  2004-04       Impact factor: 3.791

Review 7.  The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature.

Authors:  Soheil Tavakolpour
Journal:  J Res Med Sci       Date:  2016-06-14       Impact factor: 1.852

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.